AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced that the U.S. Patent and Trademark Office (USPTO) issued AcelRx Patent Number 8,202,535 entitled "Small-Volume Oral Transmucosal Dosage Forms." The patent describes a method of treating pain by administering a small-volume solid tablet containing sufentanil by adhering to the oral mucosa. This newly issued patent will provide intellectual property protection for sufentanil NanoTab based products through late 2030.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.